Positive News SentimentPositive NewsNASDAQ:ARVN Arvinas (ARVN) Stock Forecast, Price & News $20.40 -0.46 (-2.21%) (As of 05:18 PM ET) Add Compare Share Share Today's Range$20.38▼$21.3050-Day Range$20.86▼$28.2152-Week Range$20.38▼$57.96Volume329,870 shsAverage Volume445,589 shsMarket Capitalization$1.09 billionP/E RatioN/ADividend YieldN/APrice Target$64.07 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Arvinas MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside210.7% Upside$64.07 Price TargetShort InterestBearish6.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.79Based on 2 Articles This WeekInsider TradingSelling Shares$32,292 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($6.14) to ($7.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector434th out of 963 stocksPharmaceutical Preparations Industry192nd out of 451 stocks 4.4 Analyst's Opinion Consensus RatingArvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $64.07, Arvinas has a forecasted upside of 210.7% from its current price of $20.62.Amount of Analyst CoverageArvinas has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.22% of the float of Arvinas has been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Arvinas has recently decreased by 1.04%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARVN. Previous Next 2.7 News and Social Media Coverage News SentimentArvinas has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arvinas this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,292.00 in company stock.Percentage Held by InsidersOnly 2.55% of the stock of Arvinas is held by insiders.Percentage Held by Institutions86.33% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arvinas are expected to decrease in the coming year, from ($6.14) to ($7.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arvinas (NASDAQ:ARVN) StockArvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.Read More ARVN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARVN Stock News HeadlinesSeptember 8, 2023 | msn.comCantor Fitzgerald Reiterates Arvinas (ARVN) Overweight RecommendationSeptember 4, 2023 | seekingalpha.comArvinas' Potential In Treating ER+, HER2- Breast CancerSeptember 27, 2023 | UNKNOWN (Ad)The Bio-Tech Stock That Needs Your Attention!There a Few Opportunities Like This Stock! Sign Up Today And Get Our NExt Bio-Tech Alert!August 21, 2023 | msn.comCitigroup Maintains Arvinas (ARVN) Buy RecommendationAugust 17, 2023 | msn.comTruist Securities Reiterates Arvinas (ARVN) Buy RecommendationAugust 14, 2023 | benzinga.com7 Analysts Have This to Say About ArvinasAugust 10, 2023 | msn.comBarclays Maintains Arvinas (ARVN) Overweight RecommendationAugust 9, 2023 | markets.businessinsider.comBarclays Maintains Overweight Rating for Arvinas: Here's What You Need To KnowSeptember 27, 2023 | UNKNOWN (Ad)The Bio-Tech Stock That Needs Your Attention!There a Few Opportunities Like This Stock! Sign Up Today And Get Our NExt Bio-Tech Alert!August 8, 2023 | finance.yahoo.comArvinas Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 6, 2023 | finance.yahoo.comCarrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant CombinationJune 26, 2023 | markets.businessinsider.comWhat 8 Analyst Ratings Have To Say About ArvinasJune 17, 2023 | finance.yahoo.comLoss-making Arvinas (NASDAQ:ARVN) has seen earnings and shareholder returns follow the same downward trajectory over past -24%June 13, 2023 | finance.yahoo.comArvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last?June 12, 2023 | msn.comOlema, Arvinas spike after analyst remarks on breast cancer drugsJune 12, 2023 | seekingalpha.comArvinas: Nothing Interesting In The Near TermJune 10, 2023 | msn.comWedbush Reiterates Arvinas (ARVN) Neutral RecommendationJune 9, 2023 | msn.comHC Wainwright & Co. Reiterates Arvinas (ARVN) Buy RecommendationJune 9, 2023 | markets.businessinsider.com6 Analysts Have This to Say About ArvinasJune 8, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on Arvinas Holding Company (ARVN)June 8, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Buy Rating on Arvinas Holding Company (ARVN)June 8, 2023 | finance.yahoo.comArvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain MutationsJune 8, 2023 | finance.yahoo.comArvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H MutationsMay 19, 2023 | msn.comLooking Into Arvinas's Return On Capital EmployedMay 17, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)May 13, 2023 | msn.comMorgan Stanley Maintains Arvinas (ARVN) Equal-Weight RecommendationMay 10, 2023 | msn.comWhere Arvinas Stands With AnalystsSee More Headlines Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address ARVN Company Calendar Last Earnings8/08/2023Today9/27/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARVN CUSIPN/A CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees415Year FoundedN/APrice Target and Rating Average Stock Price Forecast$64.07 High Stock Price Forecast$95.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+211.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-282,500,000.00 Net Margins-191.63% Pretax Margin-178.43% Return on Equity-55.09% Return on Assets-24.48% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio3.44 Sales & Book Value Annual Sales$131.40 million Price / Sales8.37 Cash FlowN/A Price / Cash FlowN/A Book Value$10.61 per share Price / Book1.94Miscellaneous Outstanding Shares53,490,000Free Float52,121,000Market Cap$1.10 billion OptionableNot Optionable Beta1.72 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. John G. Houston Ph.D. (Age 63)Chairperson, CEO & Pres Comp: $1.08MMr. Sean A. Cassidy CPA (Age 53)CPA, M.B.A., CFO, Principal Financial Officer & Treasurer Comp: $683kDr. Ian Taylor Ph.D. (Age 60)Chief Scientific Officer Comp: $692kDr. Ronald A. Peck M.D. (Age 57)Chief Medical Officer Comp: $701.63kMr. David K. Loomis M.B.A. (Age 49)VP, Principal Accounting Officer & Chief Accounting Officer Mr. Jeff BoyleVP of Investor RelationsDr. Randy Teel Ph.D. (Age 44)Sr. VP of Corp. & Bus. Devel. Mr. Steve Weiss (Age 53)Sr. VP & Chief HR Officer Dr. John A. Grosso Ph.D. (Age 66)Sr. VP of R&D Technical Operations Ms. Angela M. Cacace Ph.D. (Age 55)Sr. VP of Neuroscience & Platform Biology More ExecutivesKey CompetitorsDisc MedicineNASDAQ:IRONTango TherapeuticsNASDAQ:TNGXGeronNASDAQ:GERNMerusNASDAQ:MRUSSyndax PharmaceuticalsNASDAQ:SNDXView All CompetitorsInsiders & InstitutionsWolverine Trading LLCBought 8,800 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemSold 1,665 shares on 8/21/2023Ownership: 0.105%Nuveen Asset Management LLCBought 120,034 shares on 8/16/2023Ownership: 0.459%Royal Bank of CanadaSold 801 shares on 8/15/2023Ownership: 0.007%Walleye Capital LLCSold 200 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ARVN Stock - Frequently Asked Questions Should I buy or sell Arvinas stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARVN shares. View ARVN analyst ratings or view top-rated stocks. What is Arvinas' stock price forecast for 2023? 15 analysts have issued 12-month price targets for Arvinas' shares. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they expect the company's stock price to reach $64.07 in the next twelve months. This suggests a possible upside of 211.6% from the stock's current price. View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts. How have ARVN shares performed in 2023? Arvinas' stock was trading at $34.21 at the beginning of the year. Since then, ARVN shares have decreased by 39.9% and is now trading at $20.56. View the best growth stocks for 2023 here. When is Arvinas' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ARVN earnings forecast. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) released its earnings results on Tuesday, August, 8th. The company reported ($1.25) earnings per share for the quarter, topping analysts' consensus estimates of ($1.65) by $0.40. The business earned $54.50 million during the quarter, compared to analyst estimates of $30.94 million. Arvinas had a negative trailing twelve-month return on equity of 55.09% and a negative net margin of 191.63%. The company's revenue was up 74.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.32) earnings per share. What ETFs hold Arvinas' stock? ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Fidelity Disruptive Medicine ETF (FMED), ALPS Medical Breakthroughs ETF (SBIO) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE) and What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD). When did Arvinas IPO? (ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO. What is Arvinas' stock symbol? Arvinas trades on the NASDAQ under the ticker symbol "ARVN." Who are Arvinas' major shareholders? Arvinas' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.17%), JPMorgan Chase & Co. (3.74%), ArrowMark Colorado Holdings LLC (3.37%), State Street Corp (2.09%), Geode Capital Management LLC (1.86%) and Candriam S.C.A. (0.88%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arvinas' stock price today? One share of ARVN stock can currently be purchased for approximately $20.56. How much money does Arvinas make? Arvinas (NASDAQ:ARVN) has a market capitalization of $1.10 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.59) on an earnings per share basis. How many employees does Arvinas have? The company employs 415 workers across the globe. How can I contact Arvinas? Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com. This page (NASDAQ:ARVN) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.